Update on gene therapy for immunodeficiencies.

Primary immune deficiencies (PID) are due to blood cell defects and can be treated with transplantation of normal hematopoietic stem cells (HSC) from another person (allogeneic). Gene therapy in which a patient's autologous HSC are genetically corrected represents an alternative treatment for patients with PID, which could avoid the immunologic risks of allogeneic HSCT and confer similar benefits. Recent clinical trials using gene therapy have led to immune restoration in patients with X-linked severe combined immune deficiency (XSCID), adenosine deaminase (ADA)-deficient SCID and chronic granulomatous disease (CGD). However, severe complications arose in several of the patients in whom the integrated retroviral vectors led to leukoproliferative disorders. New approaches using safer integrating vectors or direct correction of the defective gene underlying the PID are being developed and may lead to safer and effective gene therapy for PID.

[1]  Christof von Kalle,et al.  The genotoxic potential of retroviral vectors is strongly modulated by vector design and integration site selection in a mouse model of HSC gene therapy. , 2009, The Journal of clinical investigation.

[2]  J. Hutton,et al.  Cloning of cDNA sequences of human adenosine deaminase. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[3]  A. Schambach,et al.  Physiological promoters reduce the genotoxic risk of integrating gene vectors. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[4]  S. Rosenberg,et al.  T Lymphocyte-Directed Gene Therapy for ADA− SCID: Initial Trial Results After 4 Years , 1995, Science.

[5]  David A. Williams,et al.  Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse , 1984, Nature.

[6]  D. Hickstein,et al.  Gene therapy for leukocyte adhesion deficiency. , 2000, Current opinion in molecular therapeutics.

[7]  P. Moore,et al.  Effect of ex vivo culture of CD34+ bone marrow cells on immune reconstitution of XSCID dogs following allogeneic bone marrow transplantation. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  Ralph Scully,et al.  Mechanisms of double-strand break repair in somatic mammalian cells. , 2009, The Biochemical journal.

[9]  Alessandro Aiuti,et al.  Gene therapy for immunodeficiency due to adenosine deaminase deficiency. , 2009, The New England journal of medicine.

[10]  K. Weinberg,et al.  Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiency , 1995, Nature Medicine.

[11]  C. Dunbar,et al.  Persistence and expression of the adenosine deaminase gene for 12 years and immune reaction to gene transfer components: long-term results of the first clinical gene therapy trial. , 2003, Blood.

[12]  S. Rosenberg,et al.  The Development of Gene Therapy for the Treatment of Cancer , 1993, Annals of surgery.

[13]  J. V. Stone,et al.  Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. , 2001, Blood.

[14]  E. Giblett,et al.  Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.

[15]  L. Notarangelo,et al.  Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. , 2008, The Journal of allergy and clinical immunology.

[16]  F. Bushman,et al.  Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. , 2008, The Journal of clinical investigation.

[17]  A. Fischer,et al.  Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. , 2002, The New England journal of medicine.

[18]  J. Nolta,et al.  Engraftment and retroviral marking of CD34+ and CD34+CD38- human hematopoietic progenitors assessed in immune-deficient mice. , 1998, Blood.

[19]  James M. Allen,et al.  Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors , 2008, Nature Medicine.

[20]  S. Holland,et al.  Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[21]  R. Albertini,et al.  Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome , 1969 .

[22]  S Chandrasegaran,et al.  Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Barry L. Stoddard,et al.  High-resolution profiling of homing endonuclease binding and catalytic specificity using yeast surface display , 2009, Nucleic acids research.

[24]  B. Stoddard.  Homing endonuclease structure and function , 2005, Quarterly Reviews of Biophysics.

[25]  F. Deist,et al.  Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. , 2000, Science.

[26]  Cameron S. Osborne,et al.  LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1 , 2003, Science.

[27]  Christine Kinnon,et al.  Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. , 2008, The Journal of clinical investigation.

[28]  Christine Kinnon,et al.  Mutations in TNFRSF13B Encoding TACI Are Associated With Common Variable Immunodeficiency in Humans , 2006, Pediatrics.

[29]  M. Yamada,et al.  Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combined immune deficiency caused by adenosine deaminase deficiency. , 1998, Blood.

[30]  A. Fischer,et al.  Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation. , 2008, Blood.

[31]  B. Björkstrand.  European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. , 2001, Seminars in hematology.

[32]  M. Grez,et al.  Gene therapy of chronic granulomatous disease , 2000, Bone Marrow Transplantation.

[33]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[34]  K. Kao,et al.  Role of class-II major histocompatibility complex (MHC)-antigen-positive donor leukocytes in transfusion-induced alloimmunization to donor class-I MHC antigens. , 1998, Blood.

[35]  A. Schambach,et al.  Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[36]  Evelina Mazzolari,et al.  Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA− Immunodeficient Patients , 1995, Science.

[37]  W. Anderson,et al.  Gene-marking to trace origin of relapse after autologous bone-marrow transplantation , 1993, The Lancet.

[38]  A. Schambach,et al.  Self-inactivating retroviral vectors with improved RNA processing , 2004, Gene Therapy.

[39]  R. Gatti,et al.  Immunological reconstitution of sex-linked lymphopenic immunological deficiency. , 1968, Lancet.

[40]  David A. Williams,et al.  Colocalization of retrovirus and target cells on specific fibronectin fragments increases genetic transduction of mammalian cells , 1996, Nature Medicine.

[41]  L. Notarangelo,et al.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement , 2002, Nature Medicine.

[42]  J. Puck,et al.  Gene therapy improves immune function in preadolescents with X-linked severe combined immunodeficiency. , 2007, Blood.

[43]  J. Belli,et al.  Complete correction of the Wiskott-Aldrich syndrome by allogeneic bone-marrow transplantation. , 1978, The New England journal of medicine.

[44]  A. Miller,et al.  Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production , 1986, Molecular and cellular biology.

[45]  W. Leonard,et al.  Interleukin-2 receptor gamma chain mutation results in X-linked severe combined immunodeficiency in humans. Cell 73: 147-157. 1993. , 2008, Journal of immunology.

[46]  A. Mortellaro,et al.  Correction of ADA-SCID by Stem Cell Gene Therapy Combined with Nonmyeloablative Conditioning , 2002, Science.

[47]  K. Sugamura,et al.  gamma-c gene transfer into SCID X1 patients' B-cell lines restores normal high-affinity interleukin-2 receptor expression and function. , 1996, Blood.

[48]  A. Fischer,et al.  Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99 , 2003, The Lancet.

[49]  A. Fischer,et al.  Bone marrow gene transfer in three patients with adenosine deaminase deficiency. , 1996, Gene therapy.

[50]  J. Dick,et al.  Lentivector-mediated clonal tracking reveals intrinsic heterogeneity in the human hematopoietic stem cell compartment and culture-induced stem cell impairment. , 2004, Blood.

[51]  P. Gregory,et al.  Gene editing in human stem cells using zinc finger nucleases and integrase-defective lentiviral vector delivery , 2007, Nature Biotechnology.

[52]  P. Doherty,et al.  Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in mice , 1998, Nature Medicine.

[53]  Christof von Kalle,et al.  A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. , 2003, The New England journal of medicine.

[54]  Yang Du,et al.  Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.

[55]  B. Tr,et al.  Gene therapy for leukocyte adhesion deficiency. , 2000 .

[56]  J. Garcia,et al.  Construction and properties of retrovirus packaging cells based on gibbon ape leukemia virus , 1991, Journal of virology.

[57]  Kathryn L. Parsley,et al.  Successful reconstitution of immunity in ADA-SCID by stem cell gene therapy following cessation of PEG-ADA and use of mild preconditioning. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  J. Dick,et al.  Introduction of a selectable gene into primitive stem cells capable of long-term reconstitution of the hemopoietic system of W/Wv mice , 1985, Cell.